Gulam A. Manji
YOU?
Author Swipe
View article: A phase 0, window of opportunity study of parasympathetic stimulation with bethanechol in localized pancreatic adenocarcinoma prior to surgery
A phase 0, window of opportunity study of parasympathetic stimulation with bethanechol in localized pancreatic adenocarcinoma prior to surgery Open
Background The parasympathetic branch of the autonomic nervous system has shown tumor-suppressive effects in preclinical models of pancreatic adenocarcinoma (PDAC) by inhibiting cancer stem cells and suppressing inflammatory cytokine produ…
View article: Phase II Study of Pexidartinib Plus Sirolimus in Unresectable Malignant Peripheral Nerve Sheath Tumors Identifies M2 Macrophage Activation
Phase II Study of Pexidartinib Plus Sirolimus in Unresectable Malignant Peripheral Nerve Sheath Tumors Identifies M2 Macrophage Activation Open
PURPOSE To evaluate the preliminary efficacy and safety of the combination of pexidartinib, an inhibitor of colony-stimulating factor-1 receptor (CSF1R), and sirolimus, a mammalian target of rapamycin inhibitor, to target infiltrating M2 m…
View article: Low Bacterial Biomass in Human Pancreatic Cancer and Adjacent Normal Tissue
Low Bacterial Biomass in Human Pancreatic Cancer and Adjacent Normal Tissue Open
The gut microbiome plays an important role in the carcinogenesis of luminal gastrointestinal malignancies and response to antineoplastic therapy. Preclinical studies have suggested a role of intratumoral gammaproteobacteria in mediating re…
View article: Phase I study of intratumoral injection of talimogene laherparepvec for the treatment of advanced pancreatic cancer
Phase I study of intratumoral injection of talimogene laherparepvec for the treatment of advanced pancreatic cancer Open
Background Pancreatic ductal adenocarcinoma (PDAC) presents a redoubtable challenge due to late-stage diagnosis and limited treatment options, necessitating innovative therapeutic strategies. Methods Here, we report our results investigati…
View article: Author Correction: Tumour-selective activity of RAS-GTP inhibition in pancreatic cancer
Author Correction: Tumour-selective activity of RAS-GTP inhibition in pancreatic cancer Open
View article: Author Correction: Tumour-selective activity of RAS-GTP inhibition in pancreatic cancer
Author Correction: Tumour-selective activity of RAS-GTP inhibition in pancreatic cancer Open
View article: Data from A Phase I Study of the Combination of Pexidartinib and Sirolimus to Target Tumor-Associated Macrophages in Unresectable Sarcoma and Malignant Peripheral Nerve Sheath Tumors
Data from A Phase I Study of the Combination of Pexidartinib and Sirolimus to Target Tumor-Associated Macrophages in Unresectable Sarcoma and Malignant Peripheral Nerve Sheath Tumors Open
Purpose:To evaluate the safety and tolerability in phase I first-in-human combination therapy with pexidartinib, an inhibitor of colony-stimulating factor-1 receptor, and sirolimus, an mTOR inhibitor, to target tumor-associated macrophage …
View article: Figure S1 from A Phase I Study of the Combination of Pexidartinib and Sirolimus to Target Tumor-Associated Macrophages in Unresectable Sarcoma and Malignant Peripheral Nerve Sheath Tumors
Figure S1 from A Phase I Study of the Combination of Pexidartinib and Sirolimus to Target Tumor-Associated Macrophages in Unresectable Sarcoma and Malignant Peripheral Nerve Sheath Tumors Open
Pharmacokinetics
View article: Figure S2 from A Phase I Study of the Combination of Pexidartinib and Sirolimus to Target Tumor-Associated Macrophages in Unresectable Sarcoma and Malignant Peripheral Nerve Sheath Tumors
Figure S2 from A Phase I Study of the Combination of Pexidartinib and Sirolimus to Target Tumor-Associated Macrophages in Unresectable Sarcoma and Malignant Peripheral Nerve Sheath Tumors Open
Multiplex Immunofluorescence
View article: Table S2 from A Phase I Study of the Combination of Pexidartinib and Sirolimus to Target Tumor-Associated Macrophages in Unresectable Sarcoma and Malignant Peripheral Nerve Sheath Tumors
Table S2 from A Phase I Study of the Combination of Pexidartinib and Sirolimus to Target Tumor-Associated Macrophages in Unresectable Sarcoma and Malignant Peripheral Nerve Sheath Tumors Open
Pharmacokinetic parameters
View article: Table S1 from A Phase I Study of the Combination of Pexidartinib and Sirolimus to Target Tumor-Associated Macrophages in Unresectable Sarcoma and Malignant Peripheral Nerve Sheath Tumors
Table S1 from A Phase I Study of the Combination of Pexidartinib and Sirolimus to Target Tumor-Associated Macrophages in Unresectable Sarcoma and Malignant Peripheral Nerve Sheath Tumors Open
DLT Model Estimates
View article: Tumour-selective activity of RAS-GTP inhibition in pancreatic cancer
Tumour-selective activity of RAS-GTP inhibition in pancreatic cancer Open
View article: Table S2 from A transcriptome-based precision oncology platform for patient-therapy alignment in a diverse set of treatment resistant malignancies
Table S2 from A transcriptome-based precision oncology platform for patient-therapy alignment in a diverse set of treatment resistant malignancies Open
Prioritized drugs, prediction basis, and dosing schedule for PDX therapeutic study.
View article: Key Resources Table from A transcriptome-based precision oncology platform for patient-therapy alignment in a diverse set of treatment resistant malignancies
Key Resources Table from A transcriptome-based precision oncology platform for patient-therapy alignment in a diverse set of treatment resistant malignancies Open
Key Resources Table
View article: Table S3 from A transcriptome-based precision oncology platform for patient-therapy alignment in a diverse set of treatment resistant malignancies
Table S3 from A transcriptome-based precision oncology platform for patient-therapy alignment in a diverse set of treatment resistant malignancies Open
Detailed summary of drugs prioritized for testing in PDX models, based on rank of OncoTarget and OncoTreat predictions by –log10(Bonferroni p).
View article: Table S1 from A transcriptome-based precision oncology platform for patient-therapy alignment in a diverse set of treatment resistant malignancies
Table S1 from A transcriptome-based precision oncology platform for patient-therapy alignment in a diverse set of treatment resistant malignancies Open
Summary of enrollment for the N of 1 trial to date, including numbers by cancer type, the attempt to develop a PDX, establishment of PDX, RNASeq/VIPER profiling of PDX when established, and completion of drug testing.
View article: Table S1 from A transcriptome-based precision oncology platform for patient-therapy alignment in a diverse set of treatment resistant malignancies
Table S1 from A transcriptome-based precision oncology platform for patient-therapy alignment in a diverse set of treatment resistant malignancies Open
Summary of enrollment for the N of 1 trial to date, including numbers by cancer type, the attempt to develop a PDX, establishment of PDX, RNASeq/VIPER profiling of PDX when established, and completion of drug testing.
View article: Table S6 from A transcriptome-based precision oncology platform for patient-therapy alignment in a diverse set of treatment resistant malignancies
Table S6 from A transcriptome-based precision oncology platform for patient-therapy alignment in a diverse set of treatment resistant malignancies Open
Detailed summary of therapeutic response at end-of-study time point, organized by study group—OncoTreat, OncoTarget, or Negative control—and then stratified by each individual drug arm. The study was underpowered for statistical analyses o…
View article: Table S7 from A transcriptome-based precision oncology platform for patient-therapy alignment in a diverse set of treatment resistant malignancies
Table S7 from A transcriptome-based precision oncology platform for patient-therapy alignment in a diverse set of treatment resistant malignancies Open
Current list of cancer cell lines with available drug perturbation RNASeq profiles, which together comprise the PanACEA resource.
View article: Supplementary Figures S1-S6 from A transcriptome-based precision oncology platform for patient-therapy alignment in a diverse set of treatment resistant malignancies
Supplementary Figures S1-S6 from A transcriptome-based precision oncology platform for patient-therapy alignment in a diverse set of treatment resistant malignancies Open
Supplementary Figures S1-S6 and figure legends.
View article: Table S8 from A transcriptome-based precision oncology platform for patient-therapy alignment in a diverse set of treatment resistant malignancies
Table S8 from A transcriptome-based precision oncology platform for patient-therapy alignment in a diverse set of treatment resistant malignancies Open
List of available interactomes (gene regulatory networks) that have been generated from RNASeq datasets of patient tumor samples using the ARACNe algorithm.
View article: Table S5 from A transcriptome-based precision oncology platform for patient-therapy alignment in a diverse set of treatment resistant malignancies
Table S5 from A transcriptome-based precision oncology platform for patient-therapy alignment in a diverse set of treatment resistant malignancies Open
Comprehensive list of clinically relevant drugs screened in cell lines (not all were available at time of study). The list is divided into three sections, including one with FDA approved antineoplastics, one with experimental antineoplasti…
View article: Table S8 from A transcriptome-based precision oncology platform for patient-therapy alignment in a diverse set of treatment resistant malignancies
Table S8 from A transcriptome-based precision oncology platform for patient-therapy alignment in a diverse set of treatment resistant malignancies Open
List of available interactomes (gene regulatory networks) that have been generated from RNASeq datasets of patient tumor samples using the ARACNe algorithm.
View article: Table S3 from A transcriptome-based precision oncology platform for patient-therapy alignment in a diverse set of treatment resistant malignancies
Table S3 from A transcriptome-based precision oncology platform for patient-therapy alignment in a diverse set of treatment resistant malignancies Open
Detailed summary of drugs prioritized for testing in PDX models, based on rank of OncoTarget and OncoTreat predictions by –log10(Bonferroni p).
View article: Table S4 from A transcriptome-based precision oncology platform for patient-therapy alignment in a diverse set of treatment resistant malignancies
Table S4 from A transcriptome-based precision oncology platform for patient-therapy alignment in a diverse set of treatment resistant malignancies Open
Curated list of proteins with high-affinity inhibitor drugs for OncoTarget analysis.
View article: Table S7 from A transcriptome-based precision oncology platform for patient-therapy alignment in a diverse set of treatment resistant malignancies
Table S7 from A transcriptome-based precision oncology platform for patient-therapy alignment in a diverse set of treatment resistant malignancies Open
Current list of cancer cell lines with available drug perturbation RNASeq profiles, which together comprise the PanACEA resource.
View article: Supplementary Figures S1-S6 from A transcriptome-based precision oncology platform for patient-therapy alignment in a diverse set of treatment resistant malignancies
Supplementary Figures S1-S6 from A transcriptome-based precision oncology platform for patient-therapy alignment in a diverse set of treatment resistant malignancies Open
Supplementary Figures S1-S6 and figure legends.
View article: Table S4 from A transcriptome-based precision oncology platform for patient-therapy alignment in a diverse set of treatment resistant malignancies
Table S4 from A transcriptome-based precision oncology platform for patient-therapy alignment in a diverse set of treatment resistant malignancies Open
Curated list of proteins with high-affinity inhibitor drugs for OncoTarget analysis.
View article: Table S5 from A transcriptome-based precision oncology platform for patient-therapy alignment in a diverse set of treatment resistant malignancies
Table S5 from A transcriptome-based precision oncology platform for patient-therapy alignment in a diverse set of treatment resistant malignancies Open
Comprehensive list of clinically relevant drugs screened in cell lines (not all were available at time of study). The list is divided into three sections, including one with FDA approved antineoplastics, one with experimental antineoplasti…
View article: Key Resources Table from A transcriptome-based precision oncology platform for patient-therapy alignment in a diverse set of treatment resistant malignancies
Key Resources Table from A transcriptome-based precision oncology platform for patient-therapy alignment in a diverse set of treatment resistant malignancies Open
Key Resources Table